—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Recursion Pharmaceuticals Inc (RXRX) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for RXRX, from the same nightly bakes the boards use. Research diary readings, not advice.

Mentioned on Closelooknet 2 pieces · newest: Daily Pulse, “Pattern 03 cohort — NVIDIA equity deployments as Rubin Build-Out leading indicator” (2026-05-26)

Mentioned on Closelooknet

Where RXRX appears in the diary — 2 pieces, newest first. Every link is our own writing.

Long reads

  • Pattern 03 — NVIDIA Strategic Authority InvestmentReport · 12 May 2026The 16-Event Timeline (2023-07-12 → 2026-05-12) 2024 2025 2026 RXRX 23-07 ARM 23-09 APLD 24-09 NBIS 24-12 MRVL 25-03 CRWV 25-03 INTC 25-09 NOK 25-10 SNPS 25-12 LITE COHR 26-03 IREN 26-05 GLW 26-05 exit RXRX exit APLD exit ARM Tier 1 …

Dailies

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 1.86 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How RXRX has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 1.86 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Recursion Pharmaceuticals Inc moved 1.86% on average · correlation 0.23 · higher than 99% of US names
  • Beta, last 3 months 3.55 more rate-sensitive lately than over the year
  • On the 10 worst bond days −2.69% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +5.14% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against RXRX on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Recursion Pharmaceuticals Inc

RXRX in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Recursion Pharmaceuticals combines robotics, cell biology and data science to run drug discovery at industrial scale rather than through traditional lab-by-lab experiments. It has several candidates in early clinical trials, aimed at rare genetic disease, solid tumours, lymphoma and blood cancers, and works with larger drug makers such as Roche, Sanofi, Bayer and Takeda on parts of this pipeline. It is headquartered in Salt Lake City, Utah, and listed in the United States.
Where it sits in the stack
Recursion holds no seat in Closelooknet's Rubin index, the diary's map of the AI build-out. It sits instead in the broader healthcare and biotechnology sleeve of our universe, tracked as a user of AI-driven discovery tools rather than a supplier of AI infrastructure.
Who it is priced against
Closelooknet has not assigned Recursion a peer group. The competitor the market most often names alongside it is Exscientia, another company built around AI-driven drug discovery.
Why Closelooknet tracks it
Recursion carries no Closelooknet score and no index seat. It appears in the Pattern 03 report, which follows NVIDIA's strategic equity stakes as an early signal for the Rubin build-out, and in the Daily Pulse that tracks the resulting cohort; the most recent Daily Pulse shows Recursion had exited that tracked portfolio.
What the diary watches
The diary watches whether Recursion re-enters the Pattern 03 cohort if NVIDIA renews its investment, and whether clinical trial readouts from its pipeline draw attention back to the name.

Recursion Pharmaceuticals Inc (RXRX) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Recursion Pharmaceuticals Inc (RXRX)?

Recursion Pharmaceuticals Inc trades as RXRX on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is RXRX in a Closelooknet index?

Not currently — Recursion Pharmaceuticals Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does RXRX trade against its moving averages?

Recovery attempt under the 200-day: Trades +14.1% vs the 50-day and +5.6% vs the 200-day average, 47.3% below the 52-week high and +36.6% off the 52-week low. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Recursion Pharmaceuticals Inc trade when bond yields rise?

Over the past year Recursion Pharmaceuticals Inc had a beta of 1.86 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 99% of US names. On the 10 sessions in which long bonds fell most it moved −2.69% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about Recursion Pharmaceuticals Inc?

Recursion Pharmaceuticals Inc appears in 2 Closelooknet pieces, most recently Daily Pulse: Pattern 03 cohort — NVIDIA equity deployments as Rubin Build-Out leading indicator (2026-05-26); Report: Pattern 03 — NVIDIA Strategic Authority Investment (2026-05-12). What Closelooknet said most recently: Live cohort · 10 names Current portfolio after applying the 16-event timeline through 2026-05-26: COHR · CRWV · GLW · INTC · IREN · LITE · MRVL · NBIS · NOK · SNPS Hypothetical portfolio · $100k per signal Assumes a diary follower would… (Daily Pulse, 2026-05-26). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

What does Recursion Pharmaceuticals Inc do?

Recursion Pharmaceuticals combines robotics, cell biology and data science to run drug discovery at industrial scale rather than through traditional lab-by-lab experiments. It has several candidates in early clinical trials, aimed at rare genetic disease, solid tumours, lymphoma and blood cancers, and works with larger drug makers such as Roche, Sanofi, Bayer and Takeda on parts of this pipeline. It is headquartered in Salt Lake City, Utah, and listed in the United States. Closelooknet has not assigned Recursion a peer group. The competitor the market most often names alongside it is Exscientia, another company built around AI-driven drug discovery.

Where does Recursion Pharmaceuticals Inc sit in the AI build-out?

Recursion holds no seat in Closelooknet's Rubin index, the diary's map of the AI build-out. It sits instead in the broader healthcare and biotechnology sleeve of our universe, tracked as a user of AI-driven discovery tools rather than a supplier of AI infrastructure. Recursion carries no Closelooknet score and no index seat. It appears in the Pattern 03 report, which follows NVIDIA's strategic equity stakes as an early signal for the Rubin build-out, and in the Daily Pulse that tracks the resulting cohort; the most recent Daily Pulse shows Recursion had exited that tracked portfolio.

What does this page show?

A live price chart with SMA overlays and drawing tools for RXRX, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

same Closelooknet index seat first, then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.